Oral and intravenous ascorbic acid effectiveness on erythropoietin-hyporesponsive anemia in hemodialysis patients

The investigation of oral and intravenous ascorbic acid effectiveness on Erythropoietin-hyporesponsive anemia in hemodialysis patients referred to Gorgan 5th Azar educative & therapeutic center

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201306115864N3

Enrollment

Registered

2013-07-14

Start date

2012-10-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anemia. Anaemia in other chronic diseases classified elsewhere

Interventions

Intervention 1: In intravenous ascorbic acid (IVAA) group, 300mg intravenous vitamin C(three time weekly)for 8 weeks after each dialysis session. Intervention 2: In oral ascorbic acid (POAA) group, 50

Treatment - Drugs

In intravenous ascorbic acid (IVAA) group, 300mg intravenous vitamin C(three time weekly)for 8 weeks after each dialysis session

In oral ascorbic acid (POAA) group, 500mg vitamin C (three time weekly)for 8 weeks after each dialysis session

Eligibility

Sex/Gender

All

Age

17 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria Age between 18-70 years; At least 6 months history of hemodialysis; Having dossier in hemodialysis center; Three time hemodialysis in week and four hours for each session; duration of rHuEPO treatment = 6 months; serum ferritin level of 500 ng/mL or more, transferring saturation 2 mg/dL; Bleeding or hemolysis within 3 months; Folate level<4 ng/mL; Vitamin B12 level<200 pg/mL; simultaneous participation in another study; Pregnant women.

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

Measure	Time frame
Serum oxalate. Timepoint: Before and 8 weeks after intervention. Method of measurement: Blood examination mg/dl.	—

Primary

Measure	Time frame
Hemoglobin. Timepoint: Before and 8 weeks after intervention. Method of measurement: Blood examination (g/dl).;Hematocrit. Timepoint: Before and 8 weeks after intervention. Method of measurement: Blood examination (%).;Serum iron. Timepoint: Before and 8 weeks after intervention. Method of measurement: Blood examination (ng/ml).;Ferritin. Timepoint: Before and 8 weeks after intervention. Method of measurement: Blood examination (ng/dl).;Total iron binding capacity. Timepoint: Before and 8 weeks after intervention. Method of measurement: Blood examination (%).	—

Measure

Time frame

Hemoglobin. Timepoint: Before and 8 weeks after intervention. Method of measurement: Blood examination (g/dl).;Hematocrit. Timepoint: Before and 8 weeks after intervention. Method of measurement: Blood examination (%).;Serum iron. Timepoint: Before and 8 weeks after intervention. Method of measurement: Blood examination (ng/ml).;Ferritin. Timepoint: Before and 8 weeks after intervention. Method of measurement: Blood examination (ng/dl).;Total iron binding capacity. Timepoint: Before and 8 weeks after intervention. Method of measurement: Blood examination (%).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Shariati

Golestan Medical Sciences University

shariaty@goums.ac.ir; shariati1382@yahoo.com+98 17 1442 6900

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026